A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Sara Margolin(University of Copenhagen), Lena Carlsson(University of Gothenburg), Barbro Linderholm(Karolinska University Hospital), Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Dagny Pettersson Skøld(Karolinska University Hospital), Per Edlund(Gävle Hospital), Per Karlsson(University of Gothenburg), Per Malmström, Nils‐Olof Bengtsson, Kenneth Villman(Örebro University Hospital), Martin Söderberg(Uppsala University Hospital), Elisabet Lidbrink(Stockholm South General Hospital)
Cited by 19
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k